Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Vital Therapies Secures $16 Million for Trial of Artificial Liver Device

publication date: Oct 3, 2012
Vital Therapies, a San Diego company that is developing a device to treat liver failure, has closed a $16 million capital round from its existing investors, the first of a planned $76 million multi-stage commitment. Last year, Vital Therapies raised $2 million from Jilin Aodong Medicine and was slated to receive an additional $25 million in six months if Vital Therapies was successful in obtaining SFDA approval of its device. The approval was not secured. More details....

Stock Symbol: (SHE: 000623)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
San Francisco, USA
January 6, 2019
Use 'ChinaBio200' to get a USD200 Discount!
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China